🇺🇸 FDA
Patent

US 8951527

Radioprotectants targeting thrombospondin-1 and CD47

granted A61KA61K2039/505A61K38/39

Quick answer

US patent 8951527 (Radioprotectants targeting thrombospondin-1 and CD47) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Feb 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Feb 10 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61K, A61K2039/505, A61K38/39, A61P, A61P35/00